RIVER 3 RENAL
River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space. The company's technology has the potential to address the unmet need in several kidney diseases, by further improving the standard of care, enabling medical practitioners to treat patients in a better way. River 3 Renal was established in 2020 in New York, USA.
RIVER 3 RENAL
Industry:
Health Care Health Diagnostics Medical
Founded:
2020-01-01
Address:
New York, New York, United States
Country:
United States
Status:
Active
Total Funding:
40 M USD
Investors List
SR One
SR One investment in Series A - River 3 Renal
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series A - River 3 Renal
More informations about "River 3 Renal"
River 3 Renal - Crunchbase Company Profile & Funding
River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space. The company's technology has the potential to address the unmet need in several …See details»
River 3 Renal Corp. - Drug pipelines, Patents, Clinical trials - Patsnap
Nov 1, 2024 · Explore River 3 Renal Corp. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, Disease Domain:Endocrinology and Metabolic Disease, Technology …See details»
River 3 Renal - PitchBook
Jan 27, 2021 · Developer of novel therapies designed to target orphan diseases in the renal space. The company's technology focuses on addressing the unmet need for several kidney …See details»
Clinical Trials - Active Trials | Alport Syndrome Foundation
River 3 Renal Corp. is a drug development company focused on the development and commercialization of treatments for chronic kidney diseases. They have initiated a phase 2 …See details»
River 3 Renal - Funding, Financials, Valuation & Investors
River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space.See details»
R3R-01 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 · The goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 …See details»
Bain Capital
Narrow River Management (“Narrow River”) today announced the formation and completion of a Series A financing for two new companies – River 2 Renal Corp. (“R2R”) and River 3 Renal …See details»
Narrow River Management Announces Formation and Financing …
NEW YORK, Jan. 27, 2021 /PRNewswire-PRWeb/ -- Narrow River Management ("Narrow River") today announced the formation and completion of a Series A financing for two new companies …See details»
Wilson Sonsini Advises SR One in Two $40 Million Series A …
Jan 28, 2021 · On January 27, 2021, Narrow River Management announced the formation and completion of a Series A financing for two new companies—River 2 Renal Corp. (R2R) and …See details»
River 3 Renal - Tech Stack, Apps, Patents & Trademarks
River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space.See details»
River Renal - Bain Capital Life Sciences
River Renal is engaged in offering various pharmaceutical and healthcare related services, solutions and end products for its customers. The company is headquartered in New York, the …See details»
River Renal Company Profile 2024: Valuation, Funding & Investors ...
Information on valuation, funding, cap tables, investors, and executives for River Renal. Use the PitchBook Platform to explore the full profile.See details»
Clinical Trials Detail: Charité – Universitätsmedizin Berlin
River 3 Renal (R3R01) Short title: R3R01-ASFSGS-201 Investigated disease: Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis ; Alport Syndrome Patients …See details»
Series A - River 3 Renal - 2021-01-27 - Crunchbase
River 3 Renal raised $40000000 on 2021-01-27 in Series A. Bain Capital Life Sciences Bain Capital Life Sciences specializes in buyouts, inflection capital, growth capital, turnaround …See details»
R3R 01 - AdisInsight - Springer
R3R 01 is an orally active, small molecule that is being developed by River 3 Renal Corp. in collaboration with IQVIA Biotech for the treatment of AlportSee details»
R3R01 in Focal Segmental Glomerulosclerosis and Alport ... - ICH …
Feb 23, 2022 · R3R01 is investigational small molecule designed to decrease fat levels in certain cells in the kidney and therefore may improve kidney function and reduce damage in the …See details»
R3R01 / River 3 Renal Corp - LARVOL
Enrollment open • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Renal Disease.See details»
River 3 Renal - Updates, News, Events, Signals & Triggers
Jan 27, 2021 · River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space.See details»
NCT05267262: An ongoing trial by River 3 Renal Corp. - TrialsTracker
Jun 15, 2022 · Built by the Bennett Institute for Applied Data Science, University of Oxford. Data last updated 8 February 2024. Next planned update 5 November 2024. Problems? Feedback? …See details»
River 3 Renal - Crunchbase
River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space.See details»